

<b>Indicative List of Patent Abandonment and Rejections in Cases Where Oppositions Have Been Filed</b>			
<b>Patent/Case No.</b>	<b>Family to</b>	<b>Sandeep Rathod's Comments</b>	
806/DELNP/2010	US8629171	BMS walks away from a patent application for polymorph of a salt form. The Indian filing was facing multiple pre-grant oppositions.	
5209/DELNP/2010	US8999390	Novartis walks from Indian patent application for sustained release formulation of Octreotide. This app was facing a pre-grant opposition from Indian Pharmaceutical Alliance. Opposition filed in May 2011.	
IN201814034018	EP3681485A	Novartis walks away from Indian patent application for Tropifexor formulation.	
3470/DELNP/2015	OB listed US10040872	This App faced a pre-grant opp but Opponent dropped out. Controller refused the application.	
7400/DELNP/2014	US9108927	IPO refuses Celgene' application for salt forms of Rociletinib. Celgene did not appear for the hearing.	
1871/DELNP/2005	OB listed US7750029	Astellas walks away from Indian app for Mirabegron use in overactive bladder condition. Indian Pharmaceutical Alliance had filed opposition against in Dec 2013.	
1128/DELNP/2005	US7348028.	Biovail walks away from Indian app for controlled release Diltiazem composition. 1st pre-grant Indian opposition was filed in Oct 2010 by Indian Pharmaceutical Alliance. Opp decision in 2023.	
7083/CHENP/2015, divisional from 961/CHENP/2012;	family to US9345661	Roche walks away from subcutaneous Trastuzumab injection formulation. Indian Pharmaceutical Alliance had filed pre-grant opposition.	
IN201847003846	WO2017030146	Eisai walks away from patent for Lenvatinib dose composition for treating biliary tract cancer. Indian Pharmaceutical Alliance had filed a pre-grant opp against this App.	

1664/KOLNP/2010	US8592477	<p>IPO refused UCB' application for polymorphs of Rotigotine.</p> <p>This App had been opposed by an individual in April 2017 (who did not appear for the final hearing) - however, the Opposition was a strong one and finally accepted by IPO on multiple counts - even with UCB trying hard to counter the opp.</p> <p>Not all oppositions filed by individuals are frivolous.</p>	
6560/DELNP/2009	WO2008131149	<p>AstraZeneca walks away from an app for Saxagliptin Polymorphs.</p> <p>Indian Pharm Alliance had filed a pre-grant opp against it in Dec 2010.</p> <p>Reply statements were filed in Oct 2015.</p> <p>Final decision refusing App comes in Mar 2023.</p> <p>Now, is opp disposal period a bigger problem or frivolous opp filing?</p>	
9828/CHENP/2012		<p>IPO refuses patent to IBM. Ms. Sonal had filed pre-grant opposition and Applicant attended the opp hearing but walked away thereafter.</p> <p>So, is this strawman opposition frivolous?</p>	
2999/KOLNP/2015	US9675587	<p>IPO refuses Eluxadoline composition patent in a pre-grant opposition.</p> <p>Applicant did not appear for the hearing.</p> <p>Definitely recommend reading the decision for obviousness on composition claims.</p>	
IN201747022885, family to US1101498		<p>Merck walks away from Indian patent covering crystals of Pembrolizumab.</p> <p>This App was facing a pre-grant opp.</p>	
5850/DELNP/2012		<p>IPO refuses 5850/DELNP/2012 in a pre-grant opp.</p> <p>This Opp was filed by Ms. Sonal.</p> <p>Applicant had originally prosecuted the App but after the Opp., did not attend the opp hearing.</p> <p>So, should we still say that such opp harms an applicant?</p>	